Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopbNAber: database of broadly neutralizing HIV antibodiesTenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milkMolecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loopHIV-1 prophylactic vaccines: state of the artHIV-Host Interactions: Implications for Vaccine DesignHarnessing the protective potential of HIV-1 neutralizing antibodiesThe Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C VirusContrasting Adult and Infant Immune Responses to HIV Infection and VaccinationThe evolution within usRecent strategies targeting HIV glycans in vaccine designAdvances in structure-based vaccine designStructural insights on the role of antibodies in HIV-1 vaccine and therapyDesigning synthetic vaccines for HIVAntibody responses to envelope glycoproteins in HIV-1 infectionSerology in the 21st century: the molecular-level analysis of the serum antibody repertoireHIV-1 neutralizing antibodies: understanding nature's pathwaysHost-pathogen interaction in HIV infectionAntibodies in HIV-1 vaccine development and therapyDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1HIV broadly neutralizing antibody targetsVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteMolecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunizationStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvMaturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityMultidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class AntibodiesCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope TrimerThe Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV AntibodiesVaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesignAffinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domainsProgress in HIV-1 vaccine development.High-Throughput Sequencing-Based Immune Repertoire Study during Infectious DiseaseReverse vaccinology 2.0: Human immunology instructs vaccine antigen designTargeting host-derived glycans on enveloped viruses for antibody-based vaccine designImmunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes
P2860
Q21559473-2507EBE5-BBE3-4E06-898D-2B5AF0C5625BQ24567758-18F19365-3082-4BD9-8A67-5E57EABA681AQ24598653-E4BE0AE8-D713-4164-87E3-809E323F9132Q24616040-59745D7F-EA44-4F8D-82C1-C728FF6AF849Q26740042-C12FD326-F92A-4421-82E8-81289094CB09Q26765966-AE1C91C7-E891-4721-B1EA-F951E70DFD66Q26766153-5E36AB52-3920-48BA-BEF8-63D7A48FED75Q26767258-B5480E5B-981D-4D3F-AAEE-8E4EAB86243EQ26776518-A89D1BD0-7104-4C48-AF7A-210C37BD4B8EQ26801603-F487EE74-4831-44DE-B5AF-7BBA35FCE92FQ26823603-F3C317BE-19F5-4C52-80F8-E5CD949DDC96Q26824545-F258AC93-7796-44D4-B98D-342F481E6368Q26829461-52EDF2A4-EF1E-41D5-9A66-B23E10167B54Q26862617-B3CD5DCC-A37B-49A3-A06C-FB5E36F95C9AQ26991572-2AEC6EFF-F156-4C52-BAE1-CF964506E66BQ26997997-63F16C12-84C6-4191-BB64-6657EB8CF73AQ27000480-26DF6783-8A6F-45D6-8C5C-075E610EBDE5Q27009024-0680DA71-7422-49AF-BFD4-43E9A7148C29Q27011574-41E9B83B-E77B-44FD-83CC-28F77ED23934Q27022652-A57BEE15-5FDD-4912-A632-08E7FC49ABD8Q27025177-DE9887B7-2472-472C-AA10-FA6A3C5632C6Q27026662-76B0396E-1ECA-439E-B999-18FD2E91969DQ27319450-30459D1B-F8DB-4DD9-BBAF-8824DB105E84Q27322403-FED01A6E-037B-4094-AA52-C7CEA562A658Q27324184-DCFB91AA-EA40-4707-9767-E8B01DEC1CF4Q27643993-A317168F-F487-4C1B-82D4-FBFF3E4C9227Q27644383-BA26863A-8D56-4E5C-9C32-9B1A9317ED00Q27644415-184396C5-F7AB-450F-A6F9-F59AEB7EBF92Q27644515-4EEEFA3D-FAD8-4A62-B123-D2EB1249FEDEQ27654848-16BE8DC9-53FF-4655-A121-F5211B06E0ADQ27679353-1AADDE54-79B0-4BB9-9B9B-937F3A1F0BE0Q27680497-274393A4-BA27-4FDF-B5EF-D089ED5CD483Q27680688-2CD5CC9A-11B5-47C4-92B5-27F0C1DB983EQ27681806-63740A86-60D3-4385-A896-EDD2C47A6DE5Q27684503-FC9388C3-6B28-417E-81EB-5EF344C61921Q27693849-C5332469-28E4-43D7-A653-4E711B2BD210Q28068214-C02E3C4A-596B-438A-8BCA-92FF0809A700Q28075274-1A34C22C-8FAC-42ED-99BE-5BD46433B5F0Q28084672-7496D99F-FCEA-4102-BEC1-1D49BF37A96AQ28271300-15AD65D8-407D-433D-93B6-2209ED9A281D
P2860
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@ast
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@en
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@nl
type
label
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@ast
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@en
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@nl
prefLabel
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@ast
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@en
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@nl
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
@en
P2093
Andrew Z Fire
Anqi Zheng
Baoshan Zhang
Bette T M Korber
Chaim A Schramm
Fangping Cai
Gift Kamanga
Guang Yang
Hua-Xin Liao
P2860
P2888
P304
P3181
P356
10.1038/NATURE12053
P407
P50
P577
2013-04-25T00:00:00Z
P5875
P6179
1020216641